| Description |
1 online resource. |
| Physical Medium |
polychrome |
| Description |
text file |
| Series |
RSC drug discovery
|
|
RSC drug discovery series.
|
| Note |
Includes index. |
| Contents |
Intro -- Half Title -- Drug Discovery Series -- Title -- Copyright -- Preface -- Contents -- Chapter 1 Overview of Strategies for Solving ADMET Challenges -- 1.1 Introduction -- 1.2 Strategies by ADMET Properties -- 1.2.1 Tactics to Improve Solubility (Chapter 2) -- 1.2.2 Optimisation of Passive Permeability for Oral Absorption (Chapter 3) -- 1.2.3 Targeting Gastrointestinal Uptake Transporters (Chapter 4) -- 1.2.4 Drug Efflux Transporters: P-gp and BCRP (Chapter 5) -- 1.2.5 OATs and OCTs: The SLC22 Family of Organic Anion and Cation Transporters (Chapter 6) |
|
1.2.6 OATPs: The SLCO Family of Organic Anion Transporting Polypeptide Transporters (Chapter 7) -- 1.2.7 Bile Salt Export Pump (BSEP) Inhibition (Chapter 8) -- 1.2.8 Cytochrome P450 Metabolism (Chapter 9) -- 1.2.9 Cytochrome P450 Induction (Chapter 10) -- 1.2.10 Strategies to Mitigate CYP450 Inhibition (Chapter 11) -- 1.2.11 Aldehyde and Xanthine Oxidase Metabolism (Chapter 12) -- 1.2.12 Glucuronidation (Chapter 13) -- 1.2.13 Sulfation (Chapter 14) -- 1.2.14 Reactive Metabolites (Chapter 15) -- 1.2.15 Genotoxicity (Chapter 16) -- 1.2.16 Drug-induced Photosensitivity (Chapter 17) |
|
1.2.17 Drug-induced Phospholipidosis (Chapter 18) -- 1.2.18 Cardiac Ion Channel Inhibition (Chapter 19) -- 1.3 Strategies by Molecular Properties -- References -- Chapter 2 Tactics to Improve Solubility -- 2.1 Introduction: Relevance of Solubility for Drug Disposition -- 2.2 Definitions -- 2.2.1 Which Solubility Measure is Most Pertinent? -- 2.2.2 Solubility, Lipophilicity and pKa -- 2.2.3 General Solubility Equation (GSE) -- 2.2.4 Other Predictors: In Silico -- 2.3 Mitigation Strategies -- 2.3.1 Decrease Lipophilicity -- 2.3.2 Charge -- 2.3.3 Introduction of Polar Substituents |
|
2.3.4 Replacement of Aromatic CH by N or O -- 2.3.5 Reduce Crystal Packing and Melting Point -- 2.3.6 Salt Forms -- 2.4 Examples of Mitigation Strategies -- 2.4.1 Changing Lipophilicity, Adding Polar Groups, Twists -- 2.4.2 Solid State Structure Manipulation to Reduce Melting Point -- 2.4.3 Modulating Intramolecular Interactions -- Reducing Melting Point -- 2.4.4 Reducing Planarity -- 2.4.5 Heterocyclic Switches, Reducing Aromaticity -- 2.4.6 Heterocyclic Switch -- 2.4.7 Disruption of Planarity -- 2.4.8 Simple Changes, Big Differences -- Crystal Packing and Effect of a Twist |
|
2.4.9 Introducing Polar Clashes to Induce a Twist -- 2.4.10 Profound Effect of Methyl Substituents -- 2.4.11 Additions of a Solubilising Group -- 2.4.12 Salt Formation -- References -- Chapter 3 Optimisation of Passive Permeability for Oral Absorption -- 3.1 Introduction -- 3.1.1 Potential Mechanisms of Membrane Permeation -- 3.1.2 Strategies for Screening for Passive Permeability -- 3.1.3 Influence of Physicochemical Properties on Passive Permeability -- 3.1.4 Future Directions: Beyond Rule-of-five -- 3.1.5 Relevance -- 3.2 Mitigation Strategies -- 3.3 Examples of Mitigation Strategies |
| Summary |
The Medicinal Chemist's Guide to Solving ADMET Challenges presents state-of-the-art design strategies by a global group of experienced medicinal chemists and ADMET experts across academia and the pharmaceutical industry. |
| Local Note |
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - North America |
| Subject |
Drugs -- Testing.
|
|
Drugs -- Testing. |
|
Pharmaceutical chemistry.
|
|
Pharmaceutical chemistry. |
| Genre/Form |
Electronic books.
|
| Subject |
Medication. |
| Added Author |
Schnider, Patrick, editor.
|
| Other Form: |
Print version: Medicinal chemist's guide to solving ADMET challenges. Cambridge : Royal Society of Chemistry, 2020 9781788012270 (OCoLC)1202969953 |
| ISBN |
9781788016414 (electronic book) |
|
1788016416 (electronic book) |
|
9781839160493 (electronic book) |
|
1839160497 (electronic book) |
|
9781788012270 |
|
1788012275 |
|
